Iodine Protein Stability Assay (IPSA) ID: 2025-013

A novel assay that enhances drug development by measuring protein stabilization in the presence of drugs using biological samples.

Technology Overview

The Iodine Protein Stability Assay (IPSA) developed at Brigham Young University is a cutting-edge technology designed to improve the drug development process. It measures the stabilization of proteins when bound to drugs in complex biological samples such as blood. By utilizing mass spectrometry, IPSA can quantify the binding affinity of drugs across thousands of proteins simultaneously, offering insights into the drug's impact on protein stability under physiological conditions. This method stands to revolutionize the assessment of drug safety and efficacy by identifying off-target drug interactions.

Key Advantages

• Enables quantification of drug binding affinity across thousands of proteins in complex mixtures
• Assesses the impact of genetic and lifestyle factors on drug efficacy
• Facilitates prediction of individual responses to drugs, optimizing treatment plans
• Utilizes mass spectrometry for detailed insights into structural changes in proteins upon drug binding

Problems Addressed

• Challenges in identifying off-target drug interactions in complex biological samples
• Difficulties in assessing the impact of genetic and lifestyle factors on drug efficacy
• Limited capabilities in predicting individual responses to drugs
• Constraints of traditional assays in quantifying drug-protein interactions on a large scale

Market Applications

• Drug development and safety assessment
• Personalized medicine, optimizing treatments based on individual genetic and lifestyle factors
• Pharmaceutical research, particularly in the early stages of drug discovery
• Academic and industrial research focusing on protein-drug interactions

Additional Information

Technology ID: 2025-013
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025